Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 15/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106814 | 0.90 | F10 (0.48) | NPC1ALOX15HTTRAB9AF10 | |
| SCHEMBL6106784 | 0.86 | F10 (0.52) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6107563 | 0.85 | F10 (0.59) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6109182 | 0.84 | NPC1 (0.51) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6108224 | 0.84 | F10 (0.49) | F10MEN1KMT2A | |
| SCHEMBL6112192 | 0.83 | NPC1 (0.50) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6109506 | 0.83 | F10 (0.51) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6107816 | 0.82 | NPC1 (0.49) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6107304 | 0.82 | NPC1 (0.49) | NPC1ALOX15HTTRAB9ASMN1; SMN2 | |
| SCHEMBL6107885 | 0.82 | F10 (0.48) | NPC1ALOX15HTTRAB9AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129245-B2 | Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots | ELI LILLY AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050282862-A1 | Aromatic amides | BEIGHT DOUGLAS W | 2005-12-22 | — | — | US | disclosed |
| EP-1140903-B1 | AROMATIC AMIDES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6759414-B2 | ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS | ELI LILLY AND COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20040029874-A1 | Aromatic amides | BEIGHT DOUGLAS WADE (US) | 2004-02-12 | — | — | US | disclosed |
| US-6635657-B1 | Pyridine derivatives; anticoagulants | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| EP-1140903-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029874-A1 | Aromatic amides | F11, F12, F5 | NPC1 1659/4885ALOX15 2156/4885HTT 2573/4885 |
| US-20050282862-A1 | Aromatic amides | F11, F12, F5 | NPC1 1659/4885ALOX15 2156/4885HTT 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.